GFAP and Alzheimer disease: Figure 2 summarizes the odds ratio (OR) and 95% confidence intervals (CI) across all biomarkers at all 3 time points; GFAP was the only biomarker to significantly predict AD converters vs CU at all three time points including 10 years prior to symptom onset (OR = 2.24, p = 0.0013); 5 years prior to symptom onset (OR = 1.56, p = 0.0062); and at onset (OR = 1.50, p < 0.0001).